Alzheimer Disease

Can Alzheimer disease research offer the key to effective treatment?

Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA.

Is our research about Alzheimer disease wrong?

Study shows promising results for early detection and prevention efforts.

Top-line data for study is expected in late 2022, early 2023.

Compelling new book discusses love, Alzheimer disease, and medical aid in dying.

Individuals with depression may be at a greater risk to develop late-onset Alzheimer disease, but a new study suggests depression onset may help predict Alzheimer disease.

How can you communicate the diagnosis in a way that relieves suffering and helps patients and their caregivers prepare for the future?

This donepezil transdermal system helps with the treatment on mild, moderate, or severe dementia of the Alzheimer type.

Research also finds surprising results in patients with bipolar affective disorder.

The American Academy of Neurology issued a position statement for mental health professionals, warning them to carefully discuss the benefits and known harms of aducanumab.

A new study finds amyloid plaques accelerate the breakup of neurotransmitters, worsening neurodegenerative diseases like Alzheimer disease.

More potential good news for treating Alzheimer disease, as an 18-month open-label extension for lecanemab allows for its breakthrough status.

Apathy occurs throughout the spectrum of neurocognitive disorders, but it is easy to mistake for other conditions, like depression. How can clinicians identify apathy, and treat it?

Following criticism for its wide-labeled June approval, the FDA has decided to narrow the patient recommendation for aducanumab.

How can volunteering to play video games help brain research?

Donanemab for the treatment of Alzheimer disease has received Breakthrough Therapy designation from the FDA.

This one-of-a-kind Alzheimer disease treatment targets the amyloid beta plaques in the brain, potentially slowing cognitive decline.

Gene expressions in microglia cells may explain why some of them are ineffective and allow dementia to progress.

This monoclonal antibody showed significant slowing of decline in patients with Alzheimer disease.

Aducanumab is named 1 of the 5 “Drugs to Watch” for 2021.

A study on a new Alzheimer disease vaccine lacks concrete numbers.

Cognitive impairment is not always associated with dementia. For this reason, a full comprehensive history is an integral component of any assessment. Take the quiz to learn more.

A new formulation of dexmedetomidine meets primary and secondary endpoints in recently completed study.

A new treatment for hallucinations and delusions in individuals with Alzheimer disease may be on the horizon.

New developments in Alzheimer disease treatment and research.

The Lumipulse® G β-Amyloid Ratio in vitro diagnostic test was filed for 510(k) premarket clearance.

A new study associates a gene that facilitates neuron communication in the nervous system with memory loss.

Good news in the fight against Alzheimer disease, with major progress in new, innovative treatments.

How can psychiatrists help caregivers deal with behavioral disturbances at home, without the possibility of an in-person doctor’s appointment? In this video, Marc E. Agronin, MD, offers tips for helping patients with Alzheimer disease and other dementias.